Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to US Equities

US Equities · Finance research note

REGN — Regeneron Pharmaceuticals

Research and analysis only
View analysis Browse US Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 20.66%
Profit Margins 29.65%
Return on Equity 14.55%
Return on Assets 6.13%
Free Float 0.1B
Dividend Yield 0.61%
Short Int % Utilisation 3.03%

2.2 Growth

Metric Value
Revenue Growth 19.0%
Free Cash Flow 3.27B
EBITDA 12.59 (Ratio)
Enterprise Value 55.16B
EV/Revenue 3.7
EV/EBITDA 12.59

Revenue growth of 19.0% indicates steady, moderate expansion.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* 47.55%
Risk / Std Dev (Ann.)* 33.56%
1-Year Price Return* 39.19%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $803.48
52-Week Range $541.00 – $821.11
Observation Count 251 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in US$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2025 FY2024
Revenue Reported revenue $14.34B $14.20B
Net income Reported net income $4.50B $4.41B
Total assets Year-end reported balance $40.56B $37.76B
Shareholders’ equity Year-end reported balance $31.26B $29.35B
Net margin Net income ÷ revenue 31.41% 31.07%
Asset turnover Revenue ÷ total assets 0.3536x 0.3761x
Equity multiplier Total assets ÷ shareholders’ equity 1.2976x 1.2864x
ROE Net margin × asset turnover × equity multiplier 14.41% 15.03%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue $14.34B
Prior annual revenue $14.20B
EBIT $5.27B
Tax rate 13.88%
NOPAT = EBIT × (1 − tax rate) $4.54B
Forecast start-growth basis 0.99%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT $4.54B
Add: depreciation & amortisation $543.70M
Less: capital expenditure -$1.21B
Less/(add): working-capital cash-flow movement $532.60M
Current unlevered FCFF $4.41B

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 0.99% $4.59B $549.09M -$1.23B $537.88M $4.45B $4.33B
2 1.37% $4.65B $556.61M -$1.07B $545.25M $4.68B $4.31B
3 1.75% $4.73B $566.33M -$915.27M $554.77M $4.94B $4.31B
4 2.12% $4.83B $578.35M -$756.53M $566.55M $5.22B $4.31B
5 2.50% $4.95B $592.81M -$592.81M $580.71M $5.53B $4.33B

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 0.19
Cost of equity 5.75%
Pre-tax cost of debt 1.62%
WACC 5.61%
WACC validation requires assumption review

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value $182.33B
Implied terminal EV / EBITDA 28.74x
Terminal value as % of enterprise value 86.54%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF $21.59B
Present value of terminal value $138.78B
Indicated enterprise value $160.37B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value $160.37B
Less: gross interest-bearing debt $2.71B
Add: cash and equivalents $8.61B
Add: affiliate investments $0.00
Less: minority interests $0.00
Indicated common equity value $166.27B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 108,600,000.00
Share-count basis reported diluted weighted-average shares
Current market price $819.70
DCF indicative value per share $1,531.02
Indicative value vs. market price 86.78%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range review required
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 4/4 evidenced checks
Lynch-inspired balance-and-growth checks 4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:47:23.062449 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation input Value
Regional factor set US
Factor-return currency USD
Issuer-return basis USD adjusted total return
Estimation window 2025-08-19 to 2026-06-30
Aligned daily observations 217
Minimum observation requirement 120
Currency conversion for HK listings not required

Fama–French Three-Factor and Five-Factor Results

Diagnostic FF3 FF5
Annualised alpha 1.63% 9.71%
Adjusted R² 0.05 0.05
Annualised residual volatility 32.53% 32.35%
Factor loading (t-statistic) FF3 FF5
Market excess return (Mkt-RF) 0.34 (1.80) 0.51 (2.32)
Size (SMB) 0.61 (2.37) 0.62 (2.23)
Value (HML) -0.03 (-0.14) -0.20 (-0.72)
Profitability (RMW) NM 0.28 (1.22)
Investment (CMA) NM 0.26 (0.64)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

us-equitystockequityregnhealth-carebiotechnologynasdaq